|
1
|
Jackson CC, Medeiros LJ and Miranda RN:
8p11 myeloproliferative syndrome: A review. Hum Pathol. 41:461–476.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li F, Zhai YP, Tang YM, Wang LP and Wan
PJ: Identification of a novel partner gene, TPR, fused to FGFR1 in
8p11 myeloproliferative syndrome. Genes Chromosomes Cancer.
51:890–897. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gervais C, Dano L, Perrusson N, Hélias C,
Jeandidier E, Galoisy AC, Ittel A, Herbrecht R, Bilger K and
Mauvieux L: A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel
partner gene, RANBP2/NUP358, in a
myeloproliferative/myelodysplastic neoplasm. Leukemia.
27:1186–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura Y, Ito Y, Wakimoto N, Kakegawa E,
Uchida Y and Bessho M: A novel fusion of SQSTM1 and FGFR1 in a
patient with acute myelomonocytic leukemia with t(5;8)(q35;p11)
translocation. Blood Cancer J. 4:e2652014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim SY, Kim JE, Park S and Kim HK:
Molecular identification of a TPR-FGFR1 fusion transcript in an
adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma,
and a t(1;8)(q25;p11.2). Cancer Genet. 207:258–262. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grand EK, Chase AJ, Heath C, Rahemtulla A
and Cross NC: Targeting FGFR3 in multiple myeloma: Inhibition of
t(4;14)-positive cells by SU5402 and PD173074. Leukemia.
18:962–966. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen J, Deangelo DJ, Kutok JL, Williams
IR, Lee BH, Wadleigh M, Duclos N, Cohen S, Adelsperger J, Okabe R,
et al: PKC412 inhibits the zinc finger 198-fibroblast growth factor
receptor 1 fusion tyrosine kinase and is active in treatment of
stem cell myeloproliferative disorder. Proc Natl Acad Sci USA.
101:14479–14484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chase A, Grand FH and Cross NC: Activity
of TKI258 against primary cells and cell lines with FGFR1 fusion
genes associated with the 8p11 myeloproliferative syndrome. Blood.
110:3729–3734. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wasag B, Lierman E, Meeus P, Cools J and
Vandenberghe P: The kinase inhibitor TKI258 is active against the
novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic
leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 96:922–926.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chase A, Bryant C, Score J and Cross NC:
Ponatinib as targeted therapy for FGFR1 fusions associated with the
8p11 myeloproliferative syndrome. Haematologica. 98:103–106. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gavine PR, Mooney L, Kilgour E, Thomas AP,
Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et
al: AZD4547: An orally bioavailable, potent, and selective
inhibitor of the fibroblast growth factor receptor tyrosine kinase
family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida C, Takeuchi M and Sadahira Y: A
novel t(1;8)(q25;p11.2) translocation associated with 8p11
myeloproliferative syndrome. Br J Haematol. 156:271–273. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim WS, Park SG, Park G, Jang SJ, Moon DS
and Kang SH: 8p11 myeloproliferative syndrome with
t(1;8)(q25;p11.2): A case report and review of the literature. Acta
Haematol. 133:101–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hase ME, Kuznetsov NV and Cordes VC: Amino
acid substitutions of coiled-coil protein Tpr abrogate anchorage to
the nuclear pore complex but not parallel, in-register
homodimerization. Mol Biol Cell. 12:2433–2452. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cordes VC, Hase ME and Muller L: Molecular
segments of protein Tpr that confer nuclear targeting and
association with the nuclear pore complex. Exp Cell Res. 245:43–56.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bangs P, Burke B, Powers C, Craig R,
Purohit A and Doxsey S: Functional analysis of Tpr: Identification
of nuclear pore complex association and nuclear localization
domains and a role in mRNA export. J Cell Biol. 143:1801–1812.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giles FJ, Mauro MJ, Hong F, Ortmann CE,
McNeill C, Woodman RC, Hochhaus A, le Coutre PD and Saglio G: Rates
of peripheral arterial occlusive disease in patients with chronic
myeloid leukemia in the chronic phase treated with imatinib,
nilotinib, or non-tyrosine kinase therapy: A retrospective cohort
analysis. Leukemia. 27:1310–1315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katoh M and Nakagama H: FGF receptors:
Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loren CP, Aslan JE, Rigg RA, Nowak MS,
Healy LD, Gruber A, Druker BJ and McCarty OJ: The BCR-ABL inhibitor
ponatinib inhibits platelet immunoreceptor tyrosine-based
activation motif (ITAM) signaling, platelet activation and
aggregate formation under shear. Thromb Res. 135:155–160. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ghatalia P, Morgan CJ, Choueiri TK, Rocha
P, Naik G and Sonpavde G: Pancreatitis with vascular endothelial
growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol
Hematol. 94:136–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schutz FA, Je Y, Richards CJ and Choueiri
TK: Meta-analysis of randomized controlled trials for the incidence
and risk of treatment-related mortality in patients with cancer
treated with vascular endothelial growth factor tyrosine kinase
inhibitors. J Clin Oncol. 30:871–877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ren M, Qin H, Ren R and Cowell JK:
Ponatinib suppresses the development of myeloid and lymphoid
malignancies associated with FGFR1 abnormalities. Leukemia.
27:32–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong S, Kang S, Gu TL, Kardar S, Fu H,
Lonial S, Khoury HJ, Khuri F and Chen J: 14-3-3 integrates
prosurvival signals mediated by the AKT and MAPK pathways in
ZNF198-FGFR1-transformed hematopoietic cells. Blood. 110:360–369.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guasch G, Ollendorff V, Borg JP, Birnbaum
D and Pébusque MJ: 8p12 stem cell myeloproliferative disorder: The
FOP-fibroblast growth factor receptor 1 fusion protein of the
t(6;8) translocation induces cell survival mediated by
mitogen-activated protein kinase and phosphatidylinositol
3-kinase/Akt/mTOR pathways. Mol Cell Biol. 21:8129–8142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hideshima T, Catley L, Yasui H, Ishitsuka
K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson
PG and Anderson KC: Perifosine, an oral bioactive novel
alkylphospholipid, inhibits Akt and induces in vitro and in vivo
cytotoxicity in human multiple myeloma cells. Blood. 107:4053–4062.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Richardson PG, Wolf J, Jakubowiak A,
Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M,
et al: Perifosine plus bortezomib and dexamethasone in patients
with relapsed/refractory multiple myeloma previously treated with
bortezomib: Results of a multicenter phase I/II trial. J Clin
Oncol. 29:4243–4249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jakubowiak AJ, Richardson PG, Zimmerman T,
Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C,
Hideshima T, et al: Perifosine plus lenalidomide and dexamethasone
in relapsed and relapsed/refractory multiple myeloma: A phase I
multiple myeloma research consortium study. Br J Haematol.
158:472–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
